Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy I-Mab stock
Learn how to easily invest in I-Mab stock.
I-Mab is a biotechnology business based in the US. I-Mab shares (IMAB) are listed on the NASDAQ and all prices are listed in US Dollars. I-Mab employs 378 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in I-Mab
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – IMAB – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
I-Mab stock price (NASDAQ: IMAB)Use our graph to track the performance of IMAB stocks over time.
I-Mab shares at a glance
|Latest market close||$11.49|
|52-week range||$8.05 - $81.47|
|50-day moving average||$11.19|
|200-day moving average||$34.86|
|Wall St. target price||$76.67|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-4.57|
Buy I-Mab shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy I-Mab stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
I-Mab price performance over time
|1 week (2022-06-24)||-6.96%|
|1 month (2022-06-02)||35.34%|
|3 months (2022-04-01)||-34.38%|
|6 months (2021-12-31)||-75.75%|
|1 year (2021-07-02)||-85.93%|
|2 years (2020-07-02)||-60.81%|
|3 years (2019-06-28)||N/A|
|5 years (2017-06-28)||N/A|
|Revenue TTM||$88 million|
|Gross profit TTM||$41.6 million|
|Return on assets TTM||-21.69%|
|Return on equity TTM||-45.78%|
|Market capitalisation||$949.6 million|
TTM: trailing 12 months
I-Mab share dividends
We're not expecting I-Mab to pay a dividend over the next 12 months.
I-Mab share price volatility
Over the last 12 months, I-Mab's shares have ranged in value from as little as $8.05 up to $81.47. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while I-Mab's is 1.0499. This would suggest that I-Mab's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd. ; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
I-Mab in the news
I-Mab Receives Top Rankings in Five Categories by Institutional Investor
I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210
Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)
Frequently asked questionsWhat percentage of I-Mab is owned by insiders or institutions?
Currently 1.074% of I-Mab shares are held by insiders and 64.043% by institutions. How many people work for I-Mab?
Latest data suggests 378 work at I-Mab. When does the fiscal year end for I-Mab?
I-Mab's fiscal year ends in December. Where is I-Mab based?
I-Mab's address is: New Bund Center, Shanghai, China, 200124 What is I-Mab's ISIN number?
I-Mab's international securities identification number is: US44975P1030 What is I-Mab's CUSIP number?
I-Mab's Committee on Uniform Securities Identification Procedures number is: 44975P103
More guides on Finder
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert